![]() ![]() Patients who are judged by the investigators to be ineligible for this study for other factors, such as patients who could not receive intravenous infusion.Patients who have participated in other interventional clinical trials within 3 months prior to screening.Female patients who are pregnant or lactating.A history of drug abuse, drug use, or alcohol dependence.Patients with mental illness, mental disorder and other disorders who cannot communicate properly.Patients who are allergic to the test drug or its ingredients, or who are intolerant to calcium channel blockers, or who are allergic to soy, soy products, eggs and egg products.Patients with chronic kidney disease (CKD) stage 5, requiring long-term regular dialysis treatment.Patients with a known history of liver failure or cirrhosis.Patients with lipid metabolism defects.Patients with clear history of secondary hypertension.Patients with acute stroke within 1 month before screening.Patients with acute coronary syndrome at screening or myocardial infarction within 1 month before screening.Patients with obstructive hypertrophic cardiomyopathy and systolic heart failure at screening time.Patients with confirmed or suspected severe aortic stenosis or aortic dissection at screening time.Patients with life-threatening clinical manifestations, such as malignant arrhythmias, respiratory failure, and severe disturbance of consciousness.Antihypertensive drugs have been used within 2 hours before the administration of test drugs.Able to understand informed consent, participate in the experiment voluntarily and sign informed consent.A potentially fertile patient is willing and required to use reliable contraceptive methods throughout the study period and for at least 3 months after initiation of test drug to avoid pregnancy in the female patient or in the male patient's partner.Patients with hypertensive emergency and sub-emergency requiring a rapid intravenous blood-pressure control: patients with SBP > 180 mmHg and/or DBP > 120 mmHg (requiring twice consecutive blood pressure measurements, 10 to 15 min apart), with or without target organ damage.Since then, the drug’s use has expanded to include many other lipophilic xenobiotics that have no antidote, such as calcium channel blockers and antipsychotics. Age ≥18 years-old and ≤75 years-old, regardless of gender IV lipid emulsion therapy originated from anesthesia literature that described its successful use in iatrogenic local anesthetic overdoses.Why Should I Register and Submit Results?.
0 Comments
Leave a Reply. |